ICCM vs. SGHT, BWAY, DRTS, SKIN, PROF, BSGM, INGN, ELMD, KRMD, and CVRX
Should you be buying IceCure Medical stock or one of its competitors? The main competitors of IceCure Medical include Sight Sciences (SGHT), Brainsway (BWAY), Alpha Tau Medical (DRTS), Beauty Health (SKIN), Profound Medical (PROF), Biosig Technologies (BSGM), Inogen (INGN), Electromed (ELMD), KORU Medical Systems (KRMD), and CVRx (CVRX). These companies are all part of the "medical equipment" industry.
IceCure Medical vs. Its Competitors
Sight Sciences (NASDAQ:SGHT) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.
55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 30.9% of Sight Sciences shares are held by insiders. Comparatively, 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, IceCure Medical had 1 more articles in the media than Sight Sciences. MarketBeat recorded 3 mentions for IceCure Medical and 2 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 0.00 equaled IceCure Medical'saverage media sentiment score.
Sight Sciences has a beta of 2.47, indicating that its share price is 147% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.
Sight Sciences presently has a consensus price target of $4.10, suggesting a potential downside of 2.96%. IceCure Medical has a consensus price target of $2.50, suggesting a potential upside of 136.07%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Sight Sciences.
Sight Sciences has a net margin of -63.24% compared to IceCure Medical's net margin of -467.37%. Sight Sciences' return on equity of -54.62% beat IceCure Medical's return on equity.
IceCure Medical has lower revenue, but higher earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Sight Sciences and IceCure Medical tied by winning 8 of the 16 factors compared between the two stocks.
Get IceCure Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ICCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IceCure Medical Competitors List
Related Companies and Tools
This page (NASDAQ:ICCM) was last updated on 7/4/2025 by MarketBeat.com Staff
